Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Could Signal Some Risk

When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 27x, you may consider Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) as a stock to avoid entirely

Simply Wall StJul 5 21:20 ET

Shenzhen Salubris Pharmaceuticals (002294.SZ): The listing application of its subsidiary SAL056 has been accepted.

On June 25th, Gelonhui reported that Shenzhen Salubris Pharmaceuticals(002294.SZ) learned recently that its subsidiary, Suzhou Shenzhen Salubris Pharmaceuticals, had its biologic drug "Injectable Teriparatide" (project code: SAL056) application for listing accepted by the National Medical Products Administration. SAL056 is a long-acting bone formation stimulator that is subcutaneously injected once a week. It is intended for the treatment of postmenopausal women with osteoporosis at high risk of fracture. Currently, there are no products of the same specifications and dosage domestically. If SAL056 is approved for listing, it will greatly improve the convenience of patient medication.

Gelonghui FinanceJun 25 04:08 ET

Do These 3 Checks Before Buying Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) For Its Upcoming Dividend

It looks like Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) is about to go ex-dividend in the next three days. The ex-dividend date occurs one day before the record date which is the day

Simply Wall StJun 14 20:48 ET

Private Companies Among Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 4.3% Last Week

Key Insights Significant control over Shenzhen Salubris Pharmaceuticals by private companies implies that the general public has more power to influence management and governance-related decisions 5

Simply Wall StJun 13 19:50 ET

Shenzhen Salubris Pharmaceuticals (002294.SZ) announced the 2023 annual equity distribution: 5 yuan per 10 shares, with the stock registration on June 18th.

Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that the company's equity distribution plan for 2023 is: based on the company's existing total share capital excluding repurchased shares, a cash dividend of RMB 5 per 10 shares will be distributed to all shareholders (including tax). The equity distribution registration date for this time is June 18, 2024, and the ex-dividend date for this distribution is June 19, 2024.

Zhitong FinanceJun 11 06:38 ET

Salubris Pharmaceuticals Gets Nod to Market Hypertension Drug

Shenzhen Salubris Pharmaceuticals (SHE:002294) received a drug registration certificate from China's National Medical Products Administration for allisartan medoxomil amlodipine tablets, according to

MT NewswiresMay 22 00:23 ET